The Experts below are selected from a list of 20325 Experts worldwide ranked by ideXlab platform
Bogusław Okopień - One of the best experts on this subject based on the ideXlab platform.
-
The effect of metformin on monocyte secretory function in simvastatin-treated patients with Impaired Fasting Glucose.
Metabolism: clinical and experimental, 2012Co-Authors: Robert Krysiak, Bogusław OkopieńAbstract:Abstract Objective This study was designed to investigate whether metformin affects monocyte secretory function in patients with Impaired Fasting Glucose receiving chronic statin therapy. Materials/Methods The study included 48 patients with Impaired Fasting Glucose treated for at least three months with simvastatin (40mg daily). These patients were randomized to either metformin (3g daily) or placebo, which was administered together with simvastatin for 90days. Plasma lipids, Glucose homeostasis markers, monocyte cytokine release and plasma C-reactive protein levels were determined before randomization and at the end of the treatment. Results Compared to placebo, metformin reduced monocyte release of tumor necrosis factor-α, interleukin-1β, interleukin-6, monocyte chemoattractant protein-1 and interleukin-8, as well as decreased plasma C-reactive protein levels, which were accompanied by an improvement in insulin sensitivity. Conclusions The obtained results suggest that metformin may inhibit monocyte secretory function and reduce systemic inflammation in statin-treated patients with prediabetes. Impaired Fasting Glucose patients with high cardiovascular risk may receive the greatest benefits from concomitant treatment with a statin and metformin.
-
Haemostatic Effects of Metformin in Simvastatin‐Treated Volunteers with Impaired Fasting Glucose
Basic & clinical pharmacology & toxicology, 2012Co-Authors: Robert Krysiak, Bogusław OkopieńAbstract:Our study investigated whether metformin has an impact on haemostasis in patients with pre-diabetes receiving statin therapy. The study included 41 simvastatin-treated patients with Impaired Fasting Glucose who were randomized to either metformin (3 g daily) or placebo. The international normalized ratio, the partial thromboplastin time, fibrinogen, factor VII coagulant activity, plasminogen activator inhibitor-1 and von Willebrand factor were assessed on the day of randomization and after 90 days of treatment. Metformin treatment reduced plasma levels/activity of the assessed haemostatic risk factors, and this effect correlated with the improvement in insulin sensitivity. The obtained results indicate that high-dose metformin produces a multi-directional beneficial effect on coagulation and fibrinolysis in patients with Impaired Fasting Glucose already receiving statin therapy. The effect of metformin on haemostasis may play a role in the prevention of atherosclerosis-related disorders and acute vascular events in this pre-diabetic state.
Beatriz Champagne - One of the best experts on this subject based on the ideXlab platform.
-
high prevalence of diabetes and Impaired Fasting Glucose in urban latin america the carmela study
Diabetic Medicine, 2009Co-Authors: Jorge Escobedo, L. V. Buitrón, Manuel Velasco, J. C. Ramírez, Rafael Hernández Hernández, Alejandro Macchia, Fabio Pellegrini, Herman Schargrodsky, Carlos Boissonnet, Beatriz ChampagneAbstract:Aims Cardiovascular risk is increased with Glucose metabolism abnormalities. Prevalence data can support public health initiatives required to address this risk. The Cardiovascular Risk Factor Multiple Evaluation in Latin America (CARMELA) study was designed to estimate the prevalence of Type 2 diabetes, Impaired Fasting Glucose and related risk factors in seven urban Latin American populations. Methods CARMELA was a cross-sectional, population-based study of 11 550 adults 25–64 years of age. With a multi-stage sample design of a probabilistic nature, approximately 1600 subjects were randomly selected in each city. Results Overall, the prevalence of diabetes was 7.0% (95% confidence intervals 6.5–7.6%). The prevalence of individuals with diabetes or Impaired Fasting Glucose increased with increasing age. In the oldest age category, 55–64 years of age, prevalence of diabetes ranged from 9 to 22% and prevalence of Impaired Fasting Glucose ranged from 3 to 6%. Only 16.3% of people with prior diagnosis of diabetes and who were receiving pharmacologic treatment, were in good glycaemic control (Fasting Glucose < 6.1 mmol/l). The prevalence of diabetes in individuals with abdominal obesity was approximately twofold higher. Participants with hypertension, elevated serum triglycerides and increased common carotid artery intima-media thickness were also more likely to have diabetes. Conclusions The prevalence of diabetes and Impaired Fasting Glucose is high in seven major Latin American cities; intervention is needed to avoid substantial medical and socio-economic consequences. CARMELA supports the associations of abdominal obesity, hypertension, elevated serum triglycerides and carotid intima-media thickness with diabetes.
-
High prevalence of diabetes and Impaired Fasting Glucose in urban Latin America: the CARMELA Study.
Diabetic medicine : a journal of the British Diabetic Association, 2009Co-Authors: Jorge Escobedo, L. V. Buitrón, Manuel Velasco, J. C. Ramírez, Rafael Hernández Hernández, Alejandro Macchia, Fabio Pellegrini, Herman Schargrodsky, Carlos Boissonnet, Beatriz ChampagneAbstract:Aims Cardiovascular risk is increased with Glucose metabolism abnormalities. Prevalence data can support public health initiatives required to address this risk. The Cardiovascular Risk Factor Multiple Evaluation in Latin America (CARMELA) study was designed to estimate the prevalence of Type 2 diabetes, Impaired Fasting Glucose and related risk factors in seven urban Latin American populations. Methods CARMELA was a cross-sectional, population-based study of 11 550 adults 25–64 years of age. With a multi-stage sample design of a probabilistic nature, approximately 1600 subjects were randomly selected in each city. Results Overall, the prevalence of diabetes was 7.0% (95% confidence intervals 6.5–7.6%). The prevalence of individuals with diabetes or Impaired Fasting Glucose increased with increasing age. In the oldest age category, 55–64 years of age, prevalence of diabetes ranged from 9 to 22% and prevalence of Impaired Fasting Glucose ranged from 3 to 6%. Only 16.3% of people with prior diagnosis of diabetes and who were receiving pharmacologic treatment, were in good glycaemic control (Fasting Glucose
Robert Krysiak - One of the best experts on this subject based on the ideXlab platform.
-
The effect of metformin on monocyte secretory function in simvastatin-treated patients with Impaired Fasting Glucose.
Metabolism: clinical and experimental, 2012Co-Authors: Robert Krysiak, Bogusław OkopieńAbstract:Abstract Objective This study was designed to investigate whether metformin affects monocyte secretory function in patients with Impaired Fasting Glucose receiving chronic statin therapy. Materials/Methods The study included 48 patients with Impaired Fasting Glucose treated for at least three months with simvastatin (40mg daily). These patients were randomized to either metformin (3g daily) or placebo, which was administered together with simvastatin for 90days. Plasma lipids, Glucose homeostasis markers, monocyte cytokine release and plasma C-reactive protein levels were determined before randomization and at the end of the treatment. Results Compared to placebo, metformin reduced monocyte release of tumor necrosis factor-α, interleukin-1β, interleukin-6, monocyte chemoattractant protein-1 and interleukin-8, as well as decreased plasma C-reactive protein levels, which were accompanied by an improvement in insulin sensitivity. Conclusions The obtained results suggest that metformin may inhibit monocyte secretory function and reduce systemic inflammation in statin-treated patients with prediabetes. Impaired Fasting Glucose patients with high cardiovascular risk may receive the greatest benefits from concomitant treatment with a statin and metformin.
-
Haemostatic Effects of Metformin in Simvastatin‐Treated Volunteers with Impaired Fasting Glucose
Basic & clinical pharmacology & toxicology, 2012Co-Authors: Robert Krysiak, Bogusław OkopieńAbstract:Our study investigated whether metformin has an impact on haemostasis in patients with pre-diabetes receiving statin therapy. The study included 41 simvastatin-treated patients with Impaired Fasting Glucose who were randomized to either metformin (3 g daily) or placebo. The international normalized ratio, the partial thromboplastin time, fibrinogen, factor VII coagulant activity, plasminogen activator inhibitor-1 and von Willebrand factor were assessed on the day of randomization and after 90 days of treatment. Metformin treatment reduced plasma levels/activity of the assessed haemostatic risk factors, and this effect correlated with the improvement in insulin sensitivity. The obtained results indicate that high-dose metformin produces a multi-directional beneficial effect on coagulation and fibrinolysis in patients with Impaired Fasting Glucose already receiving statin therapy. The effect of metformin on haemostasis may play a role in the prevention of atherosclerosis-related disorders and acute vascular events in this pre-diabetic state.
Jorge Escobedo - One of the best experts on this subject based on the ideXlab platform.
-
high prevalence of diabetes and Impaired Fasting Glucose in urban latin america the carmela study
Diabetic Medicine, 2009Co-Authors: Jorge Escobedo, L. V. Buitrón, Manuel Velasco, J. C. Ramírez, Rafael Hernández Hernández, Alejandro Macchia, Fabio Pellegrini, Herman Schargrodsky, Carlos Boissonnet, Beatriz ChampagneAbstract:Aims Cardiovascular risk is increased with Glucose metabolism abnormalities. Prevalence data can support public health initiatives required to address this risk. The Cardiovascular Risk Factor Multiple Evaluation in Latin America (CARMELA) study was designed to estimate the prevalence of Type 2 diabetes, Impaired Fasting Glucose and related risk factors in seven urban Latin American populations. Methods CARMELA was a cross-sectional, population-based study of 11 550 adults 25–64 years of age. With a multi-stage sample design of a probabilistic nature, approximately 1600 subjects were randomly selected in each city. Results Overall, the prevalence of diabetes was 7.0% (95% confidence intervals 6.5–7.6%). The prevalence of individuals with diabetes or Impaired Fasting Glucose increased with increasing age. In the oldest age category, 55–64 years of age, prevalence of diabetes ranged from 9 to 22% and prevalence of Impaired Fasting Glucose ranged from 3 to 6%. Only 16.3% of people with prior diagnosis of diabetes and who were receiving pharmacologic treatment, were in good glycaemic control (Fasting Glucose < 6.1 mmol/l). The prevalence of diabetes in individuals with abdominal obesity was approximately twofold higher. Participants with hypertension, elevated serum triglycerides and increased common carotid artery intima-media thickness were also more likely to have diabetes. Conclusions The prevalence of diabetes and Impaired Fasting Glucose is high in seven major Latin American cities; intervention is needed to avoid substantial medical and socio-economic consequences. CARMELA supports the associations of abdominal obesity, hypertension, elevated serum triglycerides and carotid intima-media thickness with diabetes.
-
High prevalence of diabetes and Impaired Fasting Glucose in urban Latin America: the CARMELA Study.
Diabetic medicine : a journal of the British Diabetic Association, 2009Co-Authors: Jorge Escobedo, L. V. Buitrón, Manuel Velasco, J. C. Ramírez, Rafael Hernández Hernández, Alejandro Macchia, Fabio Pellegrini, Herman Schargrodsky, Carlos Boissonnet, Beatriz ChampagneAbstract:Aims Cardiovascular risk is increased with Glucose metabolism abnormalities. Prevalence data can support public health initiatives required to address this risk. The Cardiovascular Risk Factor Multiple Evaluation in Latin America (CARMELA) study was designed to estimate the prevalence of Type 2 diabetes, Impaired Fasting Glucose and related risk factors in seven urban Latin American populations. Methods CARMELA was a cross-sectional, population-based study of 11 550 adults 25–64 years of age. With a multi-stage sample design of a probabilistic nature, approximately 1600 subjects were randomly selected in each city. Results Overall, the prevalence of diabetes was 7.0% (95% confidence intervals 6.5–7.6%). The prevalence of individuals with diabetes or Impaired Fasting Glucose increased with increasing age. In the oldest age category, 55–64 years of age, prevalence of diabetes ranged from 9 to 22% and prevalence of Impaired Fasting Glucose ranged from 3 to 6%. Only 16.3% of people with prior diagnosis of diabetes and who were receiving pharmacologic treatment, were in good glycaemic control (Fasting Glucose
Steven N Blair - One of the best experts on this subject based on the ideXlab platform.
-
the association between cardiorespiratory fitness and Impaired Fasting Glucose and type 2 diabetes mellitus in men
Annals of Internal Medicine, 1999Co-Authors: Ming Wei, J B Kampert, Larry W Gibbons, Tedd L Mitchell, C D Lee, Steven N BlairAbstract:Low cardiorespiratory fitness was associated with increased risk for Impaired Fasting Glucose and type 2 diabetes. A sedentary lifestyle may contribute to the progression from normal Fasting glucos...